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The identification of pathways that underlie common disease has been greatly impacted by the study of rare families
that segregate single genes with large effect. Intracranial aneurysm is a common neurological problem; the rupture
of these aneurysms constitutes a frequently catastrophic neurologic event. The pathogenesis of these aneurysms is
largely unknown, although genetic and environmental factors are believed to play a role. Previous genomewide
studies in affected relative pairs have suggested linkage to several loci, but underlying genes have not been identified.
We have identified a large kindred that segregates nonsyndromic intracranial aneurysm as a dominant trait with
high penetrance. Genomewide analysis of linkage was performed using a two-stage approach: an analysis of ∼10,000
single-nucleotide polymorphisms in the 6 living affected subjects, followed by the genotyping of simple tandem
repeats across resulting candidate intervals in all 23 kindred members. Analysis revealed significant linkage to a
single locus, with a LOD score of 4.2 at 1p34.3-p36.13 under a dominant model with high penetrance. These
findings identify a Mendelian form of intracranial aneurysm and map the location of the underlying disease locus.
Intracranial aneurysms (IAs [MIM %105800 and MIM
%608542]) represent a major public health problem.
The incidence of subarachnoid hemorrhage (SAH) due
to aneurysm rupture is 6 in 100,000, with ∼28,000 aneu-
rysmal ruptures per year; it is estimated that up to 2.3%
of the general population have undetected aneurysms
(Juvela 2002b). The consequences of SAH are cata-
strophic, with approximately half of IA ruptures result-
ing in immediate death. Those individuals who survive
the initial hemorrhage experience a 40% mortality rate
during the first month, and only 25% of those who live
past the first month recover completely (King 1997).
Given the poor prognosis of SAH due to aneurysm
rupture, surgical or endovascular intervention prior to
rupture is considered to be of paramount importance.
There is, however, no practical means for reliable early
diagnosis, except through screening studies of high-risk
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individuals with tests such as magnetic resonance an-
giography (MRA) or computerized tomography angio-
graphy (CTA). Moreover, there currently are no widely
accepted guidelines to identify these high-risk individuals
(Wermer et al. 2003).
Neither the conditions that lead to aneurysm forma-
tion nor the aneurysm ruptures are well understood.
Recent studies suggest that both environmental and ge-
netic factors contribute to the pathogenesis of IA. Risk
factors for the formation, growth, and rupture of IA
include hypertension, atherosclerosis, diabetes, and vas-
cular anatomical differences (Juvela 2002a; Ohkuma et
al. 2003). In addition, social factors such as smoking
and diet have also been suggested to play a role in the
disease (Juvela 2002b; Anderson et al. 2004).
Several lines of evidence demonstrate that genetic fac-
tors play an important role in IA pathogenesis. First, a
number of genetic diseases, such as adult polycystic kid-
ney disease (MIM #173900) (Chapman et al. 1992), Mar-
fan syndrome (MIM #154700) (ter Berg et al. 1986), glu-
cocorticoid remediable aldosteronism (MIM #103900)
(Litchfield et al. 1998), and Ehlers-Danlos syndrome type
IV (MIM #130050) (de Paepe et al. 1988), appear to
increase the risk of IA formation. Second, familial recur-
rence of nonsyndromic IA has been well described (Fox
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Figure 1 IA 20 kindred. Affected and unaffected individuals are shown as blackened and unblackened symbols, respectively. Obligate
carriers are shown as partially blackened symbols. Individuals II-5 and IV-1 were assigned an affection status of “unknown” prior to linkage
analysis and are shown as gray symbols. The genotypes of STR marker loci that span 14 cM at 1p34.3-p36.13 are shown, and segments of
the haplotype linked to the disease phenotype are enclosed in a box. An allele designated “0” indicates a failed reaction.
and Ko 1980; Morooka and Waga 1983; Maroun et al.
1986; Elshunnar and Whittle 1990). Indeed, there is a
three- to fivefold increase in risk for first-degree relatives
of affected individuals, compared with the general pop-
ulation (Stehbens 1998; Ronkainen et al. 1999).
Among familial IAs, the varied pattern of recurrence
has typically suggested complex causation. Several ge-
nomewide linkage studies that used affected sibling and/
or relative pairs have identified various loci throughout
the human genome that link to IA (Onda et al. 2001;
Olson et al. 2002; Farnham et al. 2004; van der Voet
et al. 2004). The results of these studies, however, have
been inconsistent, and no specific disease-related genes
have yet been identified. In addition, candidate-gene
studies have not yet shown a robust association with IA
(Onda et al. 2001; Hofer et al. 2003; Farnham et al.
2004; van der Voet et al. 2004).
In the context of substantial locus heterogeneity, the
power of affected sibling pair studies or affected relative
pair studies is markedly diminished (Risch and Merikan-
gas 1996). Alternatively, the identification of rare Men-
delian forms of disease can lead to the identification of
genes and pathways that might play a key role in the
pathogenesis of common, as well as rare, forms of the
disease (Lifton et al. 2001). A limitation to this approach
is that it is difficult to completely characterize and collect
extended kindreds. In the present study, we have inves-
tigated what we believe is the largest-yet-reported kindred
with IA; genomewide analysis of linkage provides signif-
icant evidence that the disease in this family is attributable
to inheritance of a single locus at 1p34.3-p36.13.
Since 1994, we have screened 13,000 patients with IAs
and identified 142 kindreds with two or more affected
members. The family investigated in this study (IA 20) is
the largest in our database and has been described else-
where (Fox and Ko 1980). At that time, there were six
members with proven IA, all in generation II (fig. 1). The
pedigree has since been extended and further character-
ized. In total, there are now 10 documented subjects with
IAs, 1 subject with distinctive multiple intracranial vessel
occlusions and extensive collateral vessel formation of un-
known etiology (subject III-3), and 1 subject with ab-
dominal aortic aneurysm (AAA) at a young age (age 32
years) (individual II-5); this latter trait is sometimes as-
Figure 2 Analysis of linkage in the IA 20 kindred from GeneChip data of affected individuals. Linkage graphs for all chromosomes are
shown; the X-axis corresponds to genetic distance (in cM), and the Y-axis shows LOD scores.
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sociated with IA (Cannon Albright et al. 2003). For the
purpose of linkage analysis, the patients with documented
IAs and the patient with multiple intracranial vascular
occlusions were classified as “affected,” and the patient
with AAA was prospectively classified as “phenotype un-
known.” There are also 12 unaffected descendents of sub-
ject I-2. Of these, 8 were asymptomatic at 130 years of
age and had negative screening results for magnetic res-
onance imaging, MRA, CTA, and/or catheter angiogram
(individuals II-3, II-6, II-12, II-14, III-1, III-2, III-8, and
IV-2); 3 offspring of unaffected subjects were asymptom-
atic at 130 years of age and did not have screening studies
(individuals III-5, III-9, and III-10); and 1 individual was
asymptomatic at !30 years of age, without screening stud-
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Table 1






II-7 ACA, left MCA 53
II-9 ACoA 40
II-15 Left MCA 29
II-16 Left MCA (SAH) 32
II-17 OphtA (SAH) 57
II-18 Right MCA, ACoA (SAH) 32
II-19 Left ICA (SAH) 29
III-3 Bilateral MCA occlusion 30
III-7 Left MCA 36
IV-3 Basilar, right MCA # 2 21
NOTE.—ACA p anterior cerebral; ACoA p anterior
communicating; ICA p internal carotid; MCA p mid-
dle cerebral; OphtA p ophthalmic arteries.
ies (individual IV-1). For linkage studies, this latter subject
was classified as “phenotype unknown,” and the others
were classified as “unaffected.”
The clinical features of the affected members are pre-
sented in table 1. Age at diagnosis of IA ranged from 21
years to 53 years by MRA or CTA prior to SAH (n p
) and from 29 years to 57 years for patients who pre-7
sented with SAH ( ). There are scant risk factors forn p 4
IA among kindred members; specifically, there is a history
of hypertension in only one individual, and, although
smoking was prevalent among both affected and unaf-
fected family members, there was no significant difference
between the two groups (8 of 10 affected individuals were
smokers, and 10 of 12 unaffected individuals were smok-
ers). Specifically, there is no history of polycystic kidney
disease (no history of end-stage renal disease and no serum
creatinine level 11.5 mg/dl), no history of Marfan syn-
drome (no history of aortic dissection, ectopia lentis, etc.),
and no history of Ehlers-Danlos syndrome (no history of
hypermobile joints, hyperextensible skin, or easy scar-
ring). Finally, in neither the affected-only genomewide
linkage analysis nor the affected-plus-unaffected analysis
(see below) was there evidence of linkage to known loci
for any of these syndromes. Members of both sexes are
affected, the trait is present in consecutive generations, all
affected members are the offspring of either known or
suspected IA cases, and approximately half the offspring
of such subjects have IA (fig. 1). These findings are con-
sistent with autosomal dominant transmission of IA with
high penetrance.
Blood samples were collected from all available family
members after the obtainment of their informed consent;
the study protocol was approved by the Yale Human
Investigations Committee. Genomic DNA was prepared
as described elsewhere (Bell et al. 1981).
We used a two-stage design in linkage analysis (Elston
et al. 1996). We first genotyped all available affected in-
dividuals ( ) by use of Affymetrix 10K GeneChips.n p 6
The SNPs genotyped on these chips provide an estimated
information content equivalent to a microsatellite screen
density of 1 marker/1–2.5 cM (Kruglyak 1997). SNP ge-
notypes were obtained by following the Affymetrix pro-
tocol for the GeneChip Mapping 10K Xba Array. Briefly,
genomic DNA was digested with XbaI; adapters were
ligated to the product and an adapter-specific primer was
used to amplify the product by PCR. The products were
purified, fragmented, and labeled with biotin-ddnTP.
Biotin-labeled DNA fragments were hybridized to the
Mapping 10K Array chip. After hybridization, arrays
were washed, stained, and scanned. Affymetrix Micro-
Array Suite 5.0 software was used to obtain raw mi-
croarray feature intensities, which were processed using
the Affymetrix Genotyping Tools software package to
derive SNP genotypes.
An average of 9,468 genotypes was scored per sub-
ject (SNP call-rate range, 91%–97%). To analyze the
GeneChip data for linkage, we created a UNIX-based
program (Chunky) that parses the data sheet into in-
dividual files per chromosome in linkage format. The
information captured includes chromosome number,
SNP markers, map distances, genotype calls, and allele
frequencies.
For the multipoint analysis of linkage, we specified the
disease locus as autosomal dominant, with penetrance
that varied from 70% to 99%, a mutant disease-gene
frequency of 0.001, and a phenocopy rate of 0.001. SNP
allele-frequency data for the white population, as supplied
by Affymetrix, were used for the analysis of linkage,
which was performed using the Allegro program (de-
CODE). This analysis identified three intervals with LOD
scores near the theoretical maximum of 1.8 (1p34.3-
p36.13, 1q31-q41, and 2p11-p14), with LOD scores of
!0 for nearly all of the remainder of the genome (fig.
2). The LOD scores were confirmed using the GENE-
HUNTER program. In an additional analysis, we speci-
fied the trait locus as X-linked dominant, with otherwise
similar estimates of the trait locus; no interval on the X
chromosome achieved a LOD score 10.2. Additional
genotyping with GeneChip of four unaffected individuals
yielded only these same three intervals with LOD scores
of 1.0. Changing the phenocopy rate had small effects
on the LOD scores and did not identify additional can-
didate intervals.
Using data from the University of California–Santa
Cruz (UCSC) Genome Browser (May 2004) (UCSC Ge-
nome Bioinformatics Web site), we identified and ge-
notyped from five to nine highly polymorphic di- and
tetranucleotide microsatellite markers across each of the
three candidate intervals in all available kindred members
( ). Genotyping for microsatellite analysis was per-n p 23
formed by PCR, with detection of fluorescent products
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Figure 3 Analysis of linkage with STR markers on 1p34.3-p36.13. An IA gene is localized to a 12.5-cM region between markers D1S199
and D1S496, with a maximum LOD score of 4.2. Multipoint analysis of linkage, for comparison of segregation of IA with marker loci, was
performed. The location of marker loci used is indicated at the top of the diagram. The Y-axis shows LOD scores. The horizontal bar indicates
the extent of the LOD-1 interval.
on an ABI 3700 sequencer (Applied Biosystems) equipped
with GeneScan and Genotyper software (Applied Bio-
systems). The results were analyzed using the Simwalk
program (we specified marker heterozygosities of 75%
and the same autosomal dominant model of the trait
locus used above, with penetrance of 70%–99%).
Our analysis diminished the evidence of linkage to
1q31-q41 and 2p11-p14 (table 2). In contrast, it dem-
onstrated that all affected members inherit the same hap-
lotype at 1p34.3-p36.13, whereas this haplotype was
transmitted to none of the unaffected members (fig. 1).
Parametric linkage analysis (with 99% penetrance spec-
ified) yielded a maximum LOD score of 4.2 at 1p34.3-
p36.13 (table 2 and fig. 3); changing estimates of marker-
allele frequencies had negligible effects on the LOD
score. The likelihood of linkage to 1p34.3-p36.13 was
nearly 1,000-fold more likely than the next-most-likely
interval at 1q31-q41 (table 2).
The LOD score peak occurs at UT646; the LOD-1
interval is flanked by loci D1S199 and D1S496 (fig. 3),
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1p34-1p36 3.4 3.9 4.2
1q31-1q41 1.3 .1 5.6
2p11-2p14 .3 2.3 6.6
NOTE.—Maximum LOD scores are reported
for 1p34-1p36, 1q31-1q41, and 2p11-2p14 for
STR markers in all family members, with vary-
ing estimates of penetrance.
which define a 12.5-cM interval that corresponds to a
15-Mb segment (from 19.3 million bp to 34.9 million
bp). This is the same interval defined by the GeneChip
analysis, which indicated a LOD-1 interval flanked by
rs950922 and rs514262 that corresponded to a 15.4
million–bp interval (from 21.3 million bp to 36.7 million
bp on 1p34.3-p36.13).
Analysis of critical recombinants supports localization
of the IA locus within the specified interval. Affected
subject II-9 is recombinant at the distal border, and sub-
ject III-7 is recombinant at the proximal border (fig. 1).
Nearly identical borders define the linked interval by
SNP analysis.
Examination of the LOD-1 interval identified ∼240
genes. Among these, a number of genes have been iden-
tified as plausible candidate genes, including polycystic
kidney disease–like 1, brain-specific angiogenesis inhib-
itor 2, fibronectin type III domain–containing gene, and
collagen type XVI a1.
To our knowledge, the present kindred is the largest
yet reported with IA, with 10 definitively affected subjects
and one likely affected subject. Genomewide analysis of
linkage in this kindred demonstrates complete linkage of
IA to a 12.5-cM segment of chromosome 1, with evidence
of linkage that substantially exceeds thresholds for sig-
nificance. The phenotyping in the kindred was clear-cut;
reclassification of the patient with multivessel occlusions
and extensive collateral growth as “phenotype unknown”
would reduce the maximum LOD score to 3.9. Moreover,
the LOD score was substantially increased by inclusion
of unaffected family members, which supports high pen-
etrance of the trait locus. It is also of note that the subject
with the early AAA inherited a segment of the linked
haplotype, which suggests that this vascular aneurysm
might be attributable to inheritance at this same locus. It
would be of interest to obtain abdominal ultrasounds in
kindred members to determine whether this phenotype
commonly cosegregates with IAs and/or linked haplo-
types. The pattern of segregation and the linkage data
indicate that this family defines a new Mendelian form
of IA that is transmitted as an autosomal dominant trait
with high penetrance. Similar to reported cases of familial
IAs, members of IA 20 presented with SAH or symptom-
atic findings at an earlier age than is typically found in
sporadic cases (Lozano and Leblanc 1987).
These findings represent a first step in the identifica-
tion of a susceptibility gene for IA. Other than young
age, there are no obvious clinical features that separate
IA in members of this family from typical cases in the
general population. It is presently unknown whether the
locus implicated in this study might play a role in other
common forms of IA. In principle, it is possible that this
might be a one-of-a-kind family with a rare mutation
that results in a highly penetrant form of IA. It is also
possible that other less-penetrant mutations in the same
gene or pathway play a role in more-common forms of
IA. To date, a number of studies have used linkage ap-
proaches to attempt to identify loci that contribute to
IA risk (de Paepe et al. 1988; Pope et al. 1990; Kuivan-
iemi et al. 1993; Takenaka et al. 1999; Onda et al. 2001;
Olson et al. 2002; Yoneyama et al. 2003; Farnham et
al. 2004). Sib pair studies from Japanese and Finnish pop-
ulations, as well as a recent study of a consanguineous
Dutch family, have identified candidate intervals (Onda
et al. 2001; Olson et al. 2002; Roos et al. 2004). The
only intervals from such studies that meet genomewide
evidence of significant linkage are 19q13.3 in the Finnish
population (van der Voet et al. 2004) and 2p13 in the
Dutch family (Roos et al. 2004).
The identification of the causative gene in IA 20 will
shed light on the pathways that lead to disease. Whether
this locus or pathway will play a role in more-common
forms of disease remains to be determined. However,
once genes that lead to IAs are identified, they may better
define the pathophysiology and natural history of an-
eurysm formation and rupture. Finally, these findings
may contribute to improved diagnostic and therapeutic
approaches to this disease.
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